enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Idecabtagene vicleucel - Wikipedia

   en.wikipedia.org/wiki/Idecabtagene_vicleucel

   Idecabtagene vicleucel, sold under the brand name Abecma, is a cell-based gene therapy to treat multiple myeloma. [3] [7] [8]The most common side effects include cytokine release syndrome (CRS), infections, fatigue, musculoskeletal pain, and a weakened immune system (hypogammaglobulinemia).

3. CAR T cell - Wikipedia

   en.wikipedia.org/wiki/CAR_T_cell

   [133] [134] Manufacturers of CAR T cells have developed alternative payment programs due to the high cost of CAR T therapy, such as by requiring payment only if the CAR T therapy induces a complete remission by a certain time point after treatment. [135] Additionally, CAR T cell therapies are not available worldwide yet. CAR T cell therapies ...

4. Multiple myeloma - Wikipedia

   en.wikipedia.org/wiki/Multiple_myeloma

   Moreover, CAR-T treatment seems to provide a deeper, ... A 2016 study concluded that stem cell transplant is the preferred treatment for multiple myeloma. [107]

5. FDA says cancer treatment CAR-T therapy may cause ... - AOL

   www.aol.com/fda-says-cancer-treatment-car...

   The black box warning that the agency has asked the companies to include states, “T-cell malignancies may occur following treatment with BCMA- and CD19-directed genetically modified autologous T ...

6. US FDA investigating safety risk of CAR-T cancer therapies - AOL

   www.aol.com/news/us-fda-investigating-safety...

   Maksim Mamonkin, a CAR-T expert at Baylor College of Medicine's Center for Cell and Gene Therapy, who oversees production of CAR-T treatments, said in clinical trials, secondary cancers are ...

7. Cellular adoptive immunotherapy - Wikipedia

   en.wikipedia.org/wiki/Cellular_adoptive...

   The major application of CAR-T immunotherapy is to treat hematological malignancies, such as multiple myeloma, chronic lymphocytic leukemia, acute lymphoblastic leukemia and lymphoma. [8] Also, CAR-T-related solid tumor treatments have become increasingly promising due to protein and cell engineering improvements. [9]